We serve Chemical Name:2-Bromo-4′-cyanoacetophenone CAS:20099-89-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-Bromo-4′-cyanoacetophenone
CAS.NO:20099-89-2
Synonyms:2-bromo-4′-cyano-acetophenone;Benzonitrile, 4-(bromoacetyl)-;MFCD00052931;4-(Bromacetyl)benzolcarbonitril;2-bromo-4′-CN-acetophenone;4-(Bromoacetyl)benzonitrile;2-Bromo-4′-cyanoacetophenone;p-Cyanophenacyl bromide;2-Br-4′-CN-acetophenone;4-(2-Bromoacetyl)benzonitrile;4-Cyanophenacyl bromide;Benzonitrile, 4-(2-bromoacetyl)-;4-(2-bromo-acetyl)-benzonitrile
Molecular Formula:C9H6BrNO
Molecular Weight:224.054
HS Code:2926909090
Physical and Chemical Properties:
Melting point:92-96 °C(lit.)
Boiling point:342.4±22.0 °C at 760 mmHg
Density:1.6±0.1 g/cm3
Index of Refraction:1.590
PSA:40.86000
Exact Mass:222.963272
LogP:1.75
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 2928 6.1/PG 2
Packing Group:II
Contact us for information like 2-bromo-4′-cyano-acetophenone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-(2-bromo-acetyl)-benzonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzonitrile, 4-(bromoacetyl)- Use and application,4-(Bromoacetyl)benzonitrile technical grade,usp/ep/jp grade.
Related News: Building on this progress, recombinant technologies have been key to optimizing the performance of biocatalytic reagents, for example by facilitating a reduction in the amount of enzyme needed to drive a reaction while at the same time increasing the yield. Ecomustine manufacturers Italian medical packaging firm Stevanato Group went public on the Big Board on July 16, raising $672 million and helping push up the fortune of the billionaire Stevanato family behind the company. sodium tetrakis(4-fluorophenyl)borate suppliers For its part, the FDA’s representative at the meeting, Doran Fink, M.D., said the drug regulator is “working as rapidly as possible to conduct a thorough and comprehensive” review of all the COVID-19 vaccines that have applied for full approval. Pfizer and Moderna recently submitted their applications for a full nod. poly(vinylidene chloride-co-acrylonitrile) vendor & factory A thorough safety and risk analysis procedure should be administered at an appropriate time with documentation that adheres to the rules and regulations set forth by the regulatory authorities. ,Building on this progress, recombinant technologies have been key to optimizing the performance of biocatalytic reagents, for example by facilitating a reduction in the amount of enzyme needed to drive a reaction while at the same time increasing the yield.
